BioCryst Pharmaceuticals BCRX Stock
BioCryst Pharmaceuticals Price Chart
BioCryst Pharmaceuticals BCRX Financial and Trading Overview
| BioCryst Pharmaceuticals stock price | 8.09 USD |
| Previous Close | 7.94 USD |
| Open | 8 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1800 |
| Day's Range | 7.9 - 8.04 USD |
| 52 Week Range | 7.2 - 15.43 USD |
| Volume | 1.53M USD |
| Avg. Volume | 2.61M USD |
| Market Cap | 1.51B USD |
| Beta (5Y Monthly) | 1.982746 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.65 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.15 USD |
BCRX Valuation Measures
| Enterprise Value | 1.86B USD |
| Trailing P/E | N/A |
| Forward P/E | -14.777778 |
| PEG Ratio (5 yr expected) | -0.19 |
| Price/Sales (ttm) | 5.2046776 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 6.438 |
| Enterprise Value/EBITDA | -14.875 |
Trading Information
BioCryst Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.982746 |
| 52-Week Change | -17.047% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.43 USD |
| 52 Week Low | 7.2 USD |
| 50-Day Moving Average | 8.2 USD |
| 200-Day Moving Average | 10.57 USD |
BCRX Share Statistics
| Avg. Volume (3 month) | 2.61M USD |
| Avg. Daily Volume (10-Days) | 1.88M USD |
| Shares Outstanding | 188.94M |
| Float | 159.93M |
| Short Ratio | 12.75 |
| % Held by Insiders | 1.07% |
| % Held by Institutions | 87.07% |
| Shares Short | 35.58M |
| Short % of Float | 21.16% |
| Short % of Shares Outstanding | 18.82% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -78.10% |
| Operating Margin (ttm) | -43.80% |
| Gross Margin | 15.90% |
| EBITDA Margin | -43.27% |
Management Effectiveness
| Return on Assets (ttm) | -15.28% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 289.68M USD |
| Revenue Per Share (ttm) | 1.55 USD |
| Quarterly Revenue Growth (yoy) | 37.79% |
| Gross Profit (ttm) | 10.94M USD |
| EBITDA | -125368000 USD |
| Net Income Avi to Common (ttm) | -226252992 USD |
| Diluted EPS (ttm) | -1.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 398.16M USD |
| Total Cash Per Share (mrq) | 2.11 USD |
| Total Debt (mrq) | 755.36M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.764 |
| Book Value Per Share (mrq) | -1.738 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -131562000 USD |
| Levered Free Cash Flow (ttm) | -114687000 USD |
Profile of BioCryst Pharmaceuticals
| Country | United States |
| State | NC |
| City | Durham |
| Address | 4505 Emperor Boulevard |
| ZIP | 27703 |
| Phone | 919 859 1302 |
| Website | https://www.biocryst.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 531 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Q&A For BioCryst Pharmaceuticals Stock
What is a current BCRX stock price?
BioCryst Pharmaceuticals BCRX stock price today per share is 8.09 USD.
How to purchase BioCryst Pharmaceuticals stock?
You can buy BCRX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioCryst Pharmaceuticals?
The stock symbol or ticker of BioCryst Pharmaceuticals is BCRX.
Which industry does the BioCryst Pharmaceuticals company belong to?
The BioCryst Pharmaceuticals industry is Biotechnology.
How many shares does BioCryst Pharmaceuticals have in circulation?
The max supply of BioCryst Pharmaceuticals shares is 207.13M.
What is BioCryst Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
BioCryst Pharmaceuticals PE Ratio is now.
What was BioCryst Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
BioCryst Pharmaceuticals EPS is -0.65 USD over the trailing 12 months.
Which sector does the BioCryst Pharmaceuticals company belong to?
The BioCryst Pharmaceuticals sector is Healthcare.
BioCryst Pharmaceuticals BCRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19654.02 USD — |
+1.35
|
6.04B USD — | 19408.18 USD — | 19666.44 USD — | — - | 6.04B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4898.75 USD — |
+0.83
|
— — | 4831.84 USD — | 4920.49 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2470.41 USD — |
+1.26
|
— — | 2440.14 USD — | 2471.62 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3110.33 USD — |
+0.69
|
— — | 3091.85 USD — | 3112.19 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4538.04 USD — |
+0.83
|
— — | 4476.06 USD — | 4558.18 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 1027.16 USD — |
+0.65
|
— — | 1015.15 USD — | 1030.67 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 24018.4 USD — |
+1.35
|
— — | 23717.98 USD — | 24033.59 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 9600.33 USD — |
+1.36
|
— — | 9479.78 USD — | 9606.85 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}